Cargando…
DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
OBJECTIVES: Although current treatment guidelines for rheumatoid arthritis (RA) suggest tapering disease-modifying anti-rheumatic drugs (DMARDs), it is unclear whether DMARD-free remission (DFR) is an achievable and sustainable outcome. Therefore, we systematically reviewed the literature to determi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299506/ https://www.ncbi.nlm.nih.gov/pubmed/32393523 http://dx.doi.org/10.1136/rmdopen-2020-001220 |
_version_ | 1783547401919791104 |
---|---|
author | Verstappen, M van Mulligen, E de Jong, P H P van der Helm-Van Mil, A H M |
author_facet | Verstappen, M van Mulligen, E de Jong, P H P van der Helm-Van Mil, A H M |
author_sort | Verstappen, M |
collection | PubMed |
description | OBJECTIVES: Although current treatment guidelines for rheumatoid arthritis (RA) suggest tapering disease-modifying anti-rheumatic drugs (DMARDs), it is unclear whether DMARD-free remission (DFR) is an achievable and sustainable outcome. Therefore, we systematically reviewed the literature to determine the prevalence and sustainability of DFR and evaluated potential predictors for DFR. METHODS: A systematic literature search was performed in March 2019 in multiple databases. All clinical trials and observational studies reporting on discontinuation of DMARDs in RA patients in remission were included. Our quality assessment included a general assessment and assessment of the description of DFR. Prevalence of DFR and its sustainability and flares during tapering and after DMARD stop were summarised. Also, potential predictors for achieving DFR were reviewed. RESULTS: From 631 articles, 51 were included, comprising 14 clinical trials and 5 observational studies. DFR definition differed, especially for the duration of DMARD-free state. Considering only high- and moderate-quality studies, DFR was achieved in 5.0%–24.3% and sustained DFR (duration>12 months) in 11.6%–19.4% (both relative to the number of patients eligible for tapering). Flares occurred frequently during DMARD tapering (41.8%–75.0%) and in the first year after achieving DFR (10.4%–11.8%), while late flares, >1 year after DMARD-stop, were infrequent (0.3%–3.5%). Many patient characteristics lacked association with DFR. Absence of autoantibodies and shared epitope alleles increased the chance of achieving DFR. CONCLUSIONS: DFR is achievable in RA and is sustainable in ~10%–20% of patients. DFR can become an important outcome measure for clinical trials and requires consistency in the definition. Considering the high rate of flares in the first year after DMARD stop, a DMARD-free follow-up of >12 months is advisable to evaluate sustainability. |
format | Online Article Text |
id | pubmed-7299506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-72995062020-06-22 DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability Verstappen, M van Mulligen, E de Jong, P H P van der Helm-Van Mil, A H M RMD Open Rheumatoid Arthritis OBJECTIVES: Although current treatment guidelines for rheumatoid arthritis (RA) suggest tapering disease-modifying anti-rheumatic drugs (DMARDs), it is unclear whether DMARD-free remission (DFR) is an achievable and sustainable outcome. Therefore, we systematically reviewed the literature to determine the prevalence and sustainability of DFR and evaluated potential predictors for DFR. METHODS: A systematic literature search was performed in March 2019 in multiple databases. All clinical trials and observational studies reporting on discontinuation of DMARDs in RA patients in remission were included. Our quality assessment included a general assessment and assessment of the description of DFR. Prevalence of DFR and its sustainability and flares during tapering and after DMARD stop were summarised. Also, potential predictors for achieving DFR were reviewed. RESULTS: From 631 articles, 51 were included, comprising 14 clinical trials and 5 observational studies. DFR definition differed, especially for the duration of DMARD-free state. Considering only high- and moderate-quality studies, DFR was achieved in 5.0%–24.3% and sustained DFR (duration>12 months) in 11.6%–19.4% (both relative to the number of patients eligible for tapering). Flares occurred frequently during DMARD tapering (41.8%–75.0%) and in the first year after achieving DFR (10.4%–11.8%), while late flares, >1 year after DMARD-stop, were infrequent (0.3%–3.5%). Many patient characteristics lacked association with DFR. Absence of autoantibodies and shared epitope alleles increased the chance of achieving DFR. CONCLUSIONS: DFR is achievable in RA and is sustainable in ~10%–20% of patients. DFR can become an important outcome measure for clinical trials and requires consistency in the definition. Considering the high rate of flares in the first year after DMARD stop, a DMARD-free follow-up of >12 months is advisable to evaluate sustainability. BMJ Publishing Group 2020-05-07 /pmc/articles/PMC7299506/ /pubmed/32393523 http://dx.doi.org/10.1136/rmdopen-2020-001220 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Rheumatoid Arthritis Verstappen, M van Mulligen, E de Jong, P H P van der Helm-Van Mil, A H M DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability |
title | DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability |
title_full | DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability |
title_fullStr | DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability |
title_full_unstemmed | DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability |
title_short | DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability |
title_sort | dmard-free remission as novel treatment target in rheumatoid arthritis: a systematic literature review of achievability and sustainability |
topic | Rheumatoid Arthritis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299506/ https://www.ncbi.nlm.nih.gov/pubmed/32393523 http://dx.doi.org/10.1136/rmdopen-2020-001220 |
work_keys_str_mv | AT verstappenm dmardfreeremissionasnoveltreatmenttargetinrheumatoidarthritisasystematicliteraturereviewofachievabilityandsustainability AT vanmulligene dmardfreeremissionasnoveltreatmenttargetinrheumatoidarthritisasystematicliteraturereviewofachievabilityandsustainability AT dejongphp dmardfreeremissionasnoveltreatmenttargetinrheumatoidarthritisasystematicliteraturereviewofachievabilityandsustainability AT vanderhelmvanmilahm dmardfreeremissionasnoveltreatmenttargetinrheumatoidarthritisasystematicliteraturereviewofachievabilityandsustainability |